AHA: Noninvasive Testing Ups LOS in Patients With Chest Pain

Share this content:
AHA: Noninvasive Testing Ups LOS in Patients With Chest Pain
AHA: Noninvasive Testing Ups LOS in Patients With Chest Pain

WEDNESDAY, Nov. 15, 2017 (HealthDay News) -- Noninvasive cardiac testing leads to longer length of stay (LOS) for patients presenting to the emergency department with chest pain, according to a study published online Nov. 14 in JAMA Internal Medicine to coincide with the American Heart Association's Scientific Sessions, being held Nov. 11 to 15 in Anaheim, California.

Samuel W. Reinhardt, M.D., from Washington University School of Medicine in St. Louis, and colleagues examined differences in outcomes with clinical evaluation and noninvasive testing (coronary computed tomographic angiography [CCTA] or stress testing) versus clinical evaluation alone in an analysis of 1,000 patients who presented to the emergency department with chest pain.

The researchers found that during the 28-day study period, patients who underwent clinical evaluation alone experienced a shorter LOS (20.3 versus 27.9 hours), lower rates of diagnostic testing and angiography (2 versus 11 percent), lower median costs ($2,261.50 versus $2,584.30), and less cumulative radiation exposure (0 versus 9.9 mSv). In the 28-day follow-up period, there was no difference in the rates of percutaneous coronary intervention, coronary artery bypass surgery, return emergency department visits, or major adverse cardiac events.

"Noninvasive cardiac testing in addition to clinical evaluation leads to longer stay, more downstream testing, more radiation exposure, and greater cost without evidence of improving clinical outcomes," the authors write.

Abstract/Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »